HOME > COMMENTARY
COMMENTARY
-
5 Major New Drugs Affected by Listing of 1st Generics
July 31, 2006
-
COMMENTARY:New Clinical Trial Stimulation Plan to Go in Tandem with New Industry Vision
July 17, 2006
-
COMMENTARY Social Security Spending to Be Cut by \1.6 Tril.↓
July 10, 2006
-
COMMENTARY Amended PAL to Remake Retail Industry
July 10, 2006
-
Generic Drug Market Sees New Era of Competition 5 articles
July 3, 2006
-
Drug Industry Reorganization in the Future ―No More Argument, Unexpected Leaders?―
June 19, 2006
-
COMMENTARY 3 articles
June 19, 2006
-
Predicting the Future Market for Smoking Cessation Aids: Will OTC Products Continue to Outsell Ethical Products?
June 5, 2006
-
Major Domestic Companies Invest More Than Ever in R&D
May 29, 2006
-
Incident in PI Trial in UK 5 articles
May 8, 2006
-
COMMENTARY 3 articles
April 24, 2006
-
New Prescription Form Shaking Things Up at Pharmacies
April 24, 2006
-
Proposed Increases in Frequency of NHI Price Revisions
April 17, 2006
-
JMA Needs to Establish New Partnership with LDP
April 17, 2006
-
COMMENTARY 4 articles
April 3, 2006
-
Tougher Pricing Policy, New Products Essential to Offset Impact of NHI Price Revision
March 27, 2006
-
No Domestic Company Moves Despite Expected Growth: Vaccine Business
March 27, 2006
-
FY2006 NHI Price Revision: Industry Succeeds in Defensive Efforts
March 13, 2006
-
Pfizer Management, Labor See Signs of Snowbreak
March 6, 2006
-
Effects of Medical Fee Revision Need to be Verified
March 6, 2006
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
